|
321 (2005 rank: 258)
BMY
43,000 |
 |
Peter R. Dolan
345 Park Ave., New York, NY 10154
212-546-4000
http://www.bms.com |
 |
| Revenues |
20,222.0 |
-7.6 |
| Profits |
3,000.0 |
25.6 |
| Assets |
28,138.0 |
-- |
| Stockholders' Equity |
11,208.0 |
-- |
| Industry: Pharmaceuticals |
| 1 |
Pfizer |
101 |
51,353 |
| 2 |
Johnson & Johnson |
104 |
50,514 |
| 3 |
GlaxoSmithKline |
143 |
39,366 |
| 4 |
Sanofi-Aventis |
159 |
35,429 |
| 5 |
Novartis |
177 |
32,212 |
| 6 |
Roche Group |
204 |
28,496 |
| 7 |
AstraZeneca |
253 |
23,950 |
| 8 |
Abbott Laboratories |
283 |
22,338 |
| 9 |
Merck |
289 |
22,012 |
| 10 |
Bristol-Myers Squibb |
321 |
20,222 |
| 11 |
Wyeth |
343 |
18,756 |
| 12 |
Eli Lilly |
464 |
14,645 |
From the July 24, 2006 issue
|
| How the Countries Stack Up |
| United States |
170 |
| Japan |
70 |
| Britain, France (tied) |
38 |
| See the rest |
| Most profitable companies |
|